Mechanistic basis for impaired B cell depletion after anti-CD20 treatment of African American with neuro-inflammatory disorders

Go Back to All Clinical Trials

Mechanistic basis for impaired B cell depletion after anti-CD20 treatment of African American with neuro-inflammatory disorders

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Neuroinflammatory Disease
Age: Between 14 years - 80 years
Gender: Male or Female

Other Inclusion Criteria:
1. Diagnosed with MS, NMO, or other neuroinflammatory disorders
2. Currently treated with infusible antiCD20 therapy (ocrelizumab or rituximab)
3. Able to give informed consent if 18 years old or older. If participant is under 18 years old, they must be able to provide assent and their parent/legal guardian must be able to provide consent
4. Self-identified African-American, or known African ancestry

You may not be eligible for this study if the following are true:

1. High-dose steroids, or intravenous immunoglobulin (IVIG) or plasma exchange (PLEX) use within 3 months of blood sample collection
2. Concurrent immunosuppressive therapy, active systemic cancer
3. Obesity (BMI > 30)

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies